MA52504A - Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations - Google Patents

Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations

Info

Publication number
MA52504A
MA52504A MA052504A MA52504A MA52504A MA 52504 A MA52504 A MA 52504A MA 052504 A MA052504 A MA 052504A MA 52504 A MA52504 A MA 52504A MA 52504 A MA52504 A MA 52504A
Authority
MA
Morocco
Prior art keywords
type
binding proteins
receptor binding
cannabinoid receptor
cannabinoid
Prior art date
Application number
MA052504A
Other languages
English (en)
Inventor
Antara Banerjee
Andrea Fanjul
Robert J Hoey
Kacey Sachen
Nikolai Suslov
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of MA52504A publication Critical patent/MA52504A/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51Complete heavy chain or Fd fragment, i.e. VH + CH1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515Complete light chain, i.e. VL + CL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/524CH2 domain
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MA052504A 2018-04-30 2019-04-29 Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations MA52504A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862664882P 2018-04-30 2018-04-30

Publications (1)

Publication Number Publication Date
MA52504A true MA52504A (fr) 2021-04-28

Family

ID=67396963

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052504A MA52504A (fr) 2018-04-30 2019-04-29 Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations

Country Status (20)

Country Link
US (2) US20220396620A1 (fr)
EP (1) EP3787746A1 (fr)
JP (2) JP7431750B2 (fr)
KR (1) KR20210005051A (fr)
CN (1) CN112218684A (fr)
AR (1) AR114436A1 (fr)
AU (1) AU2019264029A1 (fr)
BR (1) BR112020022035A2 (fr)
CA (1) CA3098416A1 (fr)
CL (1) CL2020002793A1 (fr)
CO (1) CO2020014681A2 (fr)
EA (1) EA202092593A1 (fr)
EC (1) ECSP20076576A (fr)
MA (1) MA52504A (fr)
MX (1) MX2020011498A (fr)
PE (1) PE20210419A1 (fr)
PH (1) PH12020551805A1 (fr)
SG (1) SG11202010388SA (fr)
TW (1) TW202003549A (fr)
WO (1) WO2019211665A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210419A1 (es) 2018-04-30 2021-03-08 Takeda Pharmaceuticals Co Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
WO2023242843A1 (fr) * 2022-06-17 2023-12-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Périphérisation d'antagonistes du récepteur cannabinoïde-1 à action centrale par des nanoparticules pour le traitement d'affections associées au métabolisme
WO2024022478A1 (fr) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 Anticorps se liant au récepteur cannabinoïde cb1 et son utilisation

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0098110B1 (fr) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Composition à action prolongée
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (fr) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hémoglobine liée à un poly(oxyde d'alkylène)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (fr) 1987-03-18 1988-09-22 Medical Research Council Anticorps alteres
US5006309A (en) 1988-04-22 1991-04-09 Abbott Laboratories Immunoassay device with liquid transfer between wells by washing
US5089424A (en) 1988-06-14 1992-02-18 Abbott Laboratories Method and apparatus for heterogeneous chemiluminescence assay
US5063081A (en) 1988-11-14 1991-11-05 I-Stat Corporation Method of manufacturing a plurality of uniform microfabricated sensing devices having an immobilized ligand receptor
CA2069530A1 (fr) 1991-06-03 1992-12-04 Cass J. Grandone Trousse de reactifs pour dosages immunologiques
WO1992022653A1 (fr) 1991-06-14 1992-12-23 Genentech, Inc. Procede de production d'anticorps humanises
CA2103887C (fr) 1991-12-13 2005-08-30 Gary M. Studnicka Methodes et materiaux pour la preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US7419821B2 (en) 2002-03-05 2008-09-02 I-Stat Corporation Apparatus and methods for analyte measurement and immunoassay
US20040018577A1 (en) 2002-07-29 2004-01-29 Emerson Campbell John Lewis Multiple hybrid immunoassay
US7682833B2 (en) 2003-09-10 2010-03-23 Abbott Point Of Care Inc. Immunoassay device with improved sample closure
US7723099B2 (en) 2003-09-10 2010-05-25 Abbott Point Of Care Inc. Immunoassay device with immuno-reference electrode
US8962803B2 (en) * 2008-02-29 2015-02-24 AbbVie Deutschland GmbH & Co. KG Antibodies against the RGM A protein and uses thereof
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
CA2915386A1 (fr) * 2013-06-26 2014-12-31 Amgen Inc. Proteines de liaison a l'antigene se liant aux recepteurs cb1 et leurs utilisations
WO2015148984A2 (fr) * 2014-03-27 2015-10-01 Ruiyi Inc. Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
US10277406B1 (en) * 2014-09-05 2019-04-30 Digicert, Inc. Authentication process for issuing sequence of short-lived digital certificates
US10034865B2 (en) 2015-09-10 2018-07-31 Kashiv Pharma, Llc Surfactant-free HIV protease inhibitor composition and method of manufacturing thereof
AU2016330471B2 (en) * 2015-09-30 2022-09-29 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (CB1) receptor
PE20210419A1 (es) 2018-04-30 2021-03-08 Takeda Pharmaceuticals Co Proteinas de union al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas

Also Published As

Publication number Publication date
KR20210005051A (ko) 2021-01-13
JP7431750B2 (ja) 2024-02-15
CL2020002793A1 (es) 2021-02-12
MX2020011498A (es) 2021-01-29
EP3787746A1 (fr) 2021-03-10
TW202003549A (zh) 2020-01-16
SG11202010388SA (en) 2020-11-27
US11746155B2 (en) 2023-09-05
US20210198358A1 (en) 2021-07-01
CO2020014681A2 (es) 2020-12-10
EA202092593A1 (ru) 2021-02-12
WO2019211665A1 (fr) 2019-11-07
PE20210419A1 (es) 2021-03-08
PH12020551805A1 (en) 2021-07-26
CA3098416A1 (fr) 2019-11-07
CN112218684A (zh) 2021-01-12
ECSP20076576A (es) 2021-12-30
JP2021525059A (ja) 2021-09-24
BR112020022035A2 (pt) 2021-02-02
AU2019264029A1 (en) 2020-11-19
AR114436A1 (es) 2020-09-02
JP2024059646A (ja) 2024-05-01
US20220396620A1 (en) 2022-12-15

Similar Documents

Publication Publication Date Title
MA52273A (fr) Protéines de liaison à un antigène anti-trem2 et leurs utilisations
MA44885A (fr) Protéines de liaison bispécifiques et leurs utilisations
MA42808A (fr) Anticorps de liaison à l'il-8 et leurs utilisations
MA55627A (fr) Agonistes de glp-1r et leurs utilisations
MA42821A (fr) Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
MA54555A (fr) Agonistes de glp-1r et leurs utilisations
MA46789A (fr) Molécules de liaison spécifiques d'asct2 et leurs utilisations
MA52504A (fr) Protéines de liaison du récepteur cannabinoïde de type 1 (cb1) et leurs utilisations
MA52785A (fr) Molécules de liaison dirigées contre bcma et leurs utilisations
MA52777A (fr) Agents de liaison psma et utilisations correspondantes
MA42059A (fr) Agents de liaison bispécifique à l'antigène membranaire spécifique de la prostate (psma) et utilisations de ceux-ci
MA47113A (fr) Protéines de liaison à l'antigène anti- neuropiline et leurs méthodés d'utilisation
MA46359A (fr) Protéines de liaison à l'antigène à viscosité faible et leurs procédés de préparation
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
MA43816A (fr) Protéines de liaison inductibles et méthodes d'utilisation
MA44060A (fr) Protéines de liaison à un antigène bispécifiques anti-tl1a/anti-tnf-alpha et leurs utilisations
MA46917A (fr) Anticorps anti-met, molécules de liaison à un antigène bispécifique se liant à met, et leurs procédés d'utilisation
DK3476399T3 (da) Lag-3-antistof, antigenbindende fragment deraf og farmaceutisk anvendelse deraf
MA41313A (fr) Anticorps de liaison de la protéine april modifiés
MA49512A (fr) Protéines de liaison à l'antigène anti-papillomavirus humain et leurs méthodés d'utilisation
MA50255A (fr) Protéines de liaison à nkg2d, cd16, et molécule-1 semblable à la lectine de type c (cll-1)
MA51230A (fr) Protéines f rsv stabilisées et leurs utilisations
MA53665A (fr) Agonistes du récepteur farnésoïde x et leurs utilisations
DK3930847T5 (da) Anti-mertk-antistoffer med høj affinitet og anvendelser deraf
MA56029A (fr) Molécules de liaison au tigit et pd-1/tigit